ArticleEMBO molecular medicine2026
Ketogenic diet ameliorates diabetic kidney disease but promotes renal lipid and calcium deposition.
Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The ketogenic diet (KD) is widely used for weight loss and the treatment of type 2 diabetes (T2D), yet its impact on diabetic kidney disease (DKD) remains unclear. Here, we show that KD induces weight loss, normalizes hyperglycemia, and promotes sustained ketosis, leading to improved structural and functional features of DKD in a mouse model of T2D, effects not fully recapitulated by exogenous ketone supplementation. Despite these improvements, KD promotes ectopic lipid accumulation and calcium deposition within the kidney. Mechanistically, KD lowers circulating lipids while increasing the circulating abundance of ApoB48-containing intestinal triglyceride-rich lipoproteins and enhancing renal lipid processing, fatty acid uptake, and triglyceride synthesis. In parallel, KD induces hypercalciuria and renal calcification through increased intestinal calcium absorption, driven by activation of the renal-intestinal vitamin D axis, but independent of bone resorption. Together, these findings demonstrate that KD confers renoprotective effects while inducing metabolic adaptations that may compromise renal health.
Identifiers
43003961What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.